The new guideline advocates use of plasmapheresis for treatment of severe relapses in multiple sclerosis, severe AIDP/Guillain-Barre syndrome, and short-term management of CIDP.

AIDP can become chronic inflammatory demyelinating polyneuropathy (CIDP), a neurological disorder that causes progressive weakness and loss of sensation in the arms and legs.

Chronic inflammatory demyelinating polyneuropathy: ... [as with AIDP] Due to the ... 11. Daroff RB, et al: Bradley's neurology in clinical practice. Seventh edition.

A phase 3 trial of patients with a rare neurological condition, CIDP, data demonstrate that long-term treatment with Gamunex improves and maintains health-related quality of life, a significant ...

With over 600 recognized rare neurological disorders, many patients face misdiagnosis or lengthy diagnostic journeys before proper care is provided. Only 10% of these conditions have FDA-approved ...

The ADHERE data demonstrate that VYVGART Hytrulo has a rapid onset of action, and can reduce CIDP disease progression and risk of relapse: Reduced risk of relapse: VYVGART Hytrulo reduced the risk ...